Wolff Lisa J, Wolff Jon A, Sebestyén Magdolna G
Mirus Bio, Madison, WI 53719, USA.
Hum Gene Ther. 2009 Apr;20(4):374-88. doi: 10.1089/hum.2008.088.
Intravenous hydrodynamic injections into the liver and skeletal muscle have increased the efficacy of naked DNA delivery to a level that makes therapeutically relevant gene transfer attainable. Although there are no concerns about the immunogenicity of the delivered DNA itself, transgene products that are foreign to the host can trigger an immune response and hamper the therapeutic effect. Our goal was to determine whether and to what extent some known preventive measures are applicable to these delivery methods in order to achieve longterm expression of foreign proteins in immunocompetent mice. We designed plasmid DNA vectors that expressed a marker gene under the control of either a ubiquitous or a tissue-specific promoter. We also included microRNA (miR) target sites in the transcripts in order to silence expression in antigen-presenting cells (APCs). The constructs were delivered either into muscle or liver, using outbred ICR and inbred C57BL=6 mice. The data suggest that firefly luciferase, a potent immunogen, triggered a uniform immune response only in outbred ICR mice, and only when expressed from a ubiquitous promoter. This response could not be prevented by including APC-specific miR target sites in the transcript. In contrast, the probability of immune rejection in ICR mice could be significantly diminished by using tissue-specific promoters, and under these circumstances, the silencing of transgene expression in APCs did confer some benefits. After a single hydrodynamic injection, inbred mice did not reject luciferase under any of the tested conditions for at least 8 weeks. To test whether they became tolerized, they were challenged with a second boost of a cytomegalovirus promoter-driven luciferase construct. This triggered a strong immune response, suggesting that luciferase-reactive cells from the animals' T and B cell repertoire had not been eliminated. This secondary reaction could not be prevented by silencing expression in APCs. In conclusion, for the clinical application of hydrodynamic naked DNA delivery the use of tissue-specific promoters in combination with silencing expression in APCs will increase the probability of long-term expression, but the most desirable outcome, the establishment of transgene tolerance, appears unlikely to be achieved by any of these measures.
向肝脏和骨骼肌进行静脉内流体动力学注射已将裸DNA递送的功效提高到了一个使具有治疗相关性的基因转移成为可能的水平。尽管所递送的DNA本身不存在免疫原性问题,但对于宿主而言是外来的转基因产物可引发免疫反应并妨碍治疗效果。我们的目标是确定某些已知的预防措施是否适用于这些递送方法以及适用的程度,以便在具有免疫活性的小鼠中实现外源蛋白的长期表达。我们设计了在遍在性或组织特异性启动子控制下表达标记基因的质粒DNA载体。我们还在转录本中纳入了微小RNA(miR)靶位点,以便在抗原呈递细胞(APC)中沉默表达。使用远交系ICR小鼠和近交系C57BL/6小鼠,将构建体递送至肌肉或肝脏。数据表明,萤火虫荧光素酶是一种强效免疫原,仅在远交系ICR小鼠中且仅当从遍在性启动子表达时才引发一致的免疫反应。通过在转录本中纳入APC特异性miR靶位点无法预防这种反应。相反,通过使用组织特异性启动子,ICR小鼠中免疫排斥的可能性可显著降低,在这些情况下,APC中转基因表达的沉默确实带来了一些益处。单次流体动力学注射后,近交系小鼠在任何测试条件下至少8周内都未排斥荧光素酶。为了测试它们是否产生耐受,用巨细胞病毒启动子驱动的荧光素酶构建体进行第二次加强刺激对其进行攻击。这引发了强烈的免疫反应,表明动物T和B细胞库中对荧光素酶有反应的细胞未被清除。通过在APC中沉默表达无法预防这种二次反应。总之,对于流体动力学裸DNA递送的临床应用,使用组织特异性启动子并结合在APC中沉默表达将增加长期表达的可能性,但最理想的结果,即建立转基因耐受性,似乎不太可能通过这些措施中的任何一种来实现。